China Medical System’s Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Systemic Lupus Erythematosus

CMS-D001 is an oral highly selective TYK2 inhibitor. Compared with pan-JAK inhibitors, it has less impact on other JAK family kinases,and, is expected to lower safety risks while maintaining efficacy. Compared with marketed injectable biologics, it offers the advantages of oral administration and no risk of anti-drug antibody formation, providing potential treatment convenience for patients.   If approved, CMS-D001 will provide a new treatment option for patients with SLE in Chinaand create strong synergies with innovative drugs such as Metoject, further enhancing the Group’s competitiveness in the field of autoimmune diseases.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, on 11 September 2026, the innovative drug CMS-D001 Tablets (“CMS-D001” or the “Product”) has been granted the Drug Clinical Trial Approval Notice by the National Medical Products Administration of the People’s Republic of China (“NMPA”). The approval notice was obtained on 14 September 2026. The NMPA grants consent to conduct clinical trials evaluating the safety and efficacy […]

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China, Accelerating Clinical Application

On 9 September, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China.   Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, […]

CMS Charity | Supporting Each Other Through Adversity: CMS Donated RMB 1 Million to Support Debris-Flow-Hit Area in Gyirong, Tibet

On 26 August 2026, a large-scale ice-rock avalanche in Nepal triggered a debris flow that struck Gyirong Port in Gyirong County, Shigatse, Tibet, resulting in significant casualties, missing persons and infrastructure damage. The sudden disaster has drawn widespread concern for the safety and well-being of those affected. In response, China Medical System Holdings Limited (CMS) acted swiftly to support emergency relief and recovery efforts, donating RMB 1 million in cash through the Tibet Autonomous Region Charity Federation to the disaster-affected areas of Gyirong County, Shigatse, Tibet. The donation will support emergency rescue operations, resettlement for affected residents and post-disaster reconstruction, providing tangible support to frontline responders and the basic living needs of the affected population. The pharmaceutical industry was born out of the need to save lives, and it gains its humanity through its commitment to protecting them. Guided by its founding commitment to “fulfill social responsibility and safeguard life and health,” CMS […]

CMS: Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

Second indication approved: As the first topical JAK inhibitor approved in China for the treatment of vitiligo, Lumirix®has received China approval for the additional indication of atopic dermatitis (AD), offering a novel treatment option for pediatric patients 2 years of age and older, adolescent and adult AD patients, with safety and efficacy supported by clinical data*.  Impressive Phase III AD data in China: At week 8, 63.0% of subjects achieved IGAof 0 or 1 with at least two grades of reduction from baseline, versus 9.2% for placebo; 78.0% of subjects achieved EASI 75, versus 15.4% for placebo. A comprehensive AD “treatment + care” solution: Dermavon has developeda professional AD treatment-and-care portfolio comprising Lumirix® (topical formulation, mild-to-moderate AD), Comekibart Injection (injectable biological agent, moderate-to-severe AD), CMS-D001 (oral small molecule targeted drug, moderate-to-severe AD), and the Heling Soothing Product Series (daily repair).   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce […]

Dual Growth in Turnover and Profit | CMS (867.HK, 8A8.SG) 2026 Interim Performance Report in One Picture

Secretary of the CPC Hainan Provincial Committee Feng Fei Visits Dermavon Hainan

On August 10, 2026, Mr. Feng Fei, Secretary of the Hainan Provincial Committee of the Communist Party of China (CPC), headed a delegation for an inspection tour of Dermavon Hainan, a skin health subsidiary of China Medical System. The delegation conducted an on-site review of the company’s development, innovative R&D, and construction progress of Hainan R&D and Manufacturing Base. The inspection tour was accompanied by Fan Shaojun, Member of the Standing Committee of the Hainan Provincial Committee and Secretary of the Haikou Municipal Committee; Zhang Yong, Mayor of Haikou; Yang Zhongcheng, Director-general of the Policy Research Office of the Hainan Provincial Committee; Qi Shuli, Director of the Hainan Development and Reform Commission; Ji Tiejun, Director of the Hainan Medical Products Administration; Wang Yuan, Deputy Director-General of the Hainan Provincial Department of Industry and Information Technology. During the inspection, Huang Anjun, Executive Director and CEO of Dermavon, gave a briefing to Secretary Feng and the accompanying delegation on the Company’s […]

CMS: Rxilient Obtained Commercialization Rights for Dermatology Improved New Drug Finjuve and Branded Drug Ciclopoli in Southeast Asia and Other Markets

Finjuve, animproved new drug, is the first and only topical finasteride product worldwide approved for the treatment of androgenetic alopecia. Its efficacy is comparable to oral finasteride, while showing 100-fold lower systemic exposure and less impact on serum DHT levels compared with oral finasteride, offering an effective hair-loss treatment option with lower risk. Ciclopoli, a branded drug, uses patented HPCH water-soluble transungual technology. It does not require nail filing or organic solvents to remove the film, combining strong efficacy, safety, and convenience, and offering a superior topical treatment option for onychomycosis patients. Leveraging itsestablished registration and commercialization capabilities across Southeast Asia, Rxilient will accelerate the launch of both products, injecting new momentum into business growth in the region.   Recently, the Southeast Asia business subsidiary of China Medical System (“CMS”), Rxilient Medical Pte. Ltd. (“Rxilient”), entered into a partnership with Polichem S.A., a subsidiary of Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology. Rxilient obtained […]

Dual ESG Recognition: CMS Named Among “China ESG Leaders 2026” and Honored with the “Green Supply Chain Leadership Award”

Recently, SynTao Green Finance officially released the Steady Progress for a Sustainable Future: China ESG Leaders Annual Report 2026. China Medical System Holdings Limited (“CMS” or “the Group”) was successfully named among “China ESG Leaders 2026”, recognized for its long-term dedication and outstanding practices in the Environmental, Social, and Governance (ESG) fields. Additionally, CMS was honored with the “Green Supply Chain Leadership Award” in the ESG selection hosted by Stockstar. This double recognition underscores the strong affirmation from professional institutions and the market for the Group’s sustainable development initiatives. Published by SynTao Green Finance, a leading ESG rating agency in China, the Steady Progress for a Sustainable Future: China ESG Leaders Annual Report 2026 is widely recognized for its high credibility and influence. Stockstar’s “ESG New Benchmark Awards”, themed “Innovation, Co-governance, Long-term Value”, introduced the “Green Supply Chain Leadership Award” for the first time. The award specifically focuses on corporate practices and achievements in building green, low-carbon, and responsible supply chains. As […]

China Medical System: Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is Approved for Drug Clinical Trials for Age-related Macular Degeneration

CMS-D017 is a novel selective small-molecule inhibitor of complement factor B (CFB). Through administered orally, targeting and inhibiting complement factor B,it blocks abnormal activation of the alternative complement pathway, and thereby slows the progression of complement dysregulation-related diseases such as age-related macular degeneration (“AMD”), offering a potentially superior and more convenient treatment option[1]. CMS-D017 has demonstrated favourable efficacy and safety profiles in preclinical studies. Upon approval for marketing, CMS-D017 will synergise with the marketed innovative drug Beovu®(diabetic macular oedema, etc.), the branded drug Lucentis® (neovascular age-related macular degeneration, etc.), and the exclusive drug Augentropfen Stulln Mono Eye Drops (senile macular degeneration and all forms of asthenopia), building a multi-layered, precise and comprehensive solution for ophthalmic diseases.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 15 July 2026, the Group’s self-developed innovative drug, Complement Factor B inhibitor CMS-D017 capsules (“CMS-D017” or the “Product”), obtained the Drug Clinical Trial Approval Notice […]

CMS Charity | Standing Together with Guangxi: Medical Supplies Worth Over RMB 1 Million Rushed to Disaster Areas

Recently, affected by Typhoon Maysak combined with sustained heavy rainfall, several regions in Guangxi experienced rising river levels, urban and rural flooding, and other hazards. Transportation and public services were disrupted to varying degrees, and local residents faced mounting pressures on daily life and primary healthcare access. As floodwaters recede and cleanup operations progress, post-disaster health protection efforts have entered a critical phase, including ensuring safe drinking water, environmental disinfection, and preventing intestinal diseases. In this race against the storm, CMS responded swiftly and mobilized resources without delay. Through the Shenzhen Charity Federation, the company donated medical supplies worth over RMB 1 million to the affected areas, including disinfectants and anti-diarrheal medications, to support essential healthcare services and primary-level health protection in the disaster-hit areas. The supplies have been dispatched to the front lines under the Federation’s coordination, expedited to reach those in need and contribute to disaster relief and post-disaster recovery. Safeguarding life and […]

CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus, which is consistent with the WHO recommendation for a “cocktail” therapeutic paradigm; Silevimig Injection provides immediate protection, can be manufactured at scale with standardized processes, and carries no risks of blood-borne infections. Silevimig Injection is the passive immunization product with the smallest dose for rabies, resulting in less injection volume and easier administration, which can effectively reduce patient pain and improve compliance. Silevimig Injection will provide patients with a new option for passive immunization against rabies, and efficiently synergize with the Group’s existing expert network and market resources.   China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”, trade name: 金速希®), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the […]

2026 ADA | CMS’s Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world’s largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.   About CMS-D008 CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the […]